Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine by Trück, J, Kelly, S, Jawad, S, Snape, M, Voysey, M, Pollard, A

“…We investigated immediate immunization pain in 12-month-old children randomized to receive a booster dose of either the 10- (PCV-10) or the 13-valent (PCV-13) pneumococcal conjugate vaccine. Pain was assessed using validated pain assessment tools and crying time. …”

The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis by Voysey, M, Kelly, D, Fanshawe, T, Sadarangani, M, O'Brien, K, Perera, R, Pollard, A

“…<br/><br/> Main Outcomes and Measures: Antigen-specific antibody concentration measured 1 month after priming vaccine doses, before booster vaccination, and 1 month after booster vaccine doses. …”

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules by Sadarangani, M, Sell, T, Iro, M, Snape, M, Voysey, M, Finn, A, Heath, P, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Pollard, A

“…Vaccine-naive age-matched toddlers received 2 doses of 4CMenB. …”

Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis by Khanam, F, Kim, DR, Liu, X, Voysey, M, Pitzer, VE, Zaman, K, Pollard, AJ, Qadri, F, Clemens, JD

“…<p><strong>Background:&nbsp;</strong>A cluster-randomised trial of Vi-tetanus toxoid (Vi-TT) conjugate vaccine conducted in urban Bangladeshi children found a high level of direct protection by Vi-TT but no significant vaccine herd protection. …”

The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. by O'Connor, D, Trück, J, Lazarus, R, Clutterbuck, E, Voysey, M, Jeffery, K, Pollard, A

“…A pneumococcal vaccine has been recommended in the United Kingdom for those aged &gt;65 years since 2003 to prevent pneumococcal disease. …”

The design and analysis of seroefficacy studies for typhoid conjugate vaccines by Liu, X, Pitzer, V, Pollard, A, Voysey, M

“…<strong>Background</strong> Demonstrating efficacy of new Vi-conjugate typhoid vaccines is challenging due to the cost of field trials requiring tens of thousands of participants. …”

Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial by Qadri, F, Khanam, F, Liu, X, Theiss-Nyland, K, Biswas, PK, Bhuiyan, AI, Ahmmed, F, Colin-Jones, R, Smith, N, Tonks, S, Voysey, M, Mujadidi, YF, Mazur, O, Rajib, NH, Hossen, MI, Ahmed, SU, Khan, A, Rahman, N, Babu, G, Greenland, M, Kelly, S, Ireen, M, Islam, K, O'Reilly, P, Scherrer, KS, Pitzer, VE, Neuzil, KM, Zaman, K, Pollard, AJ, Clemens, JD

“…The vaccines were well tolerated, and no serious adverse events judged to be vaccine-related were observed. …”

Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom by Kandasamy, R, Voysey, M, Collins, S, Berbers, G, Robinson, H, Noel, I, Hughes, H, Ndimah, S, Gould, K, Fry, N, Sheppard, C, Ladhani, S, Snape, M, Hinds, J, Pollard, A

“…<p><strong>Background:</strong>&nbsp;Following programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes.…”

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy by Pace, D, Khatami, A, Attard-Montalto, S, Voysey, M, Finn, A, Faust, S, Heath, P, Borrow, R, Snape, M, Pollard, A

“…Background Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. …”

Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials by Voysey, M, Pollard, A, Perera, R, Fanshawe, T

“…Sex-differences in immune responses to some vaccines have also been observed, mostly to viral vaccines in adults. …”

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy. by Trück, J, Jawad, S, Goldblatt, D, Roalfe, L, Snape, M, Voysey, M, Pollard, A

“…<h4>Background</h4> <p>Both the 13- and 10-valent pneumococcal conjugate vaccines (PCV-13 and PCV-10) are immunogenic and effective against vaccine-type pneumococcal disease when given to young children. …”

Logistics of implementing a large-scale typhoid vaccine trial in Kathmandu, Nepal by Colin-Jones, R, Shakya, M, Voysey, M, Theiss-Nyland, K, Smith, N, Pant, D, Liu, X, Tonks, S, Mazur, O, Farooq, Y, Kelly, S, Adhikari, A, Dongol, S, Karkey, A, Shrestha, S, Basnyat, B, Pollard, A

“…Typhoid fever is estimated to affect over 20 million people per year worldwide, with infants, children, and adolescents in south-central and southeast Asia experiencing the greatest burden of disease. The Typhoid Vaccine Acceleration Consortium (TyVAC) aims to support the introduction of typhoid conjugate vaccines into Gavi-eligible countries in an effort to reduce morbidity and mortality from typhoid. …”

Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal by Shakya, M, Colin-Jones, R, Theiss-Nyland, K, Voysey, M, Pant, D, Smith, N, Liu, X, Tonks, S, Mazur, O, Farooq, YG, Clarke, J, Hill, J, Adhikari, A, Dongol, S, Karkey, A, Bajracharya, B, Kelly, S, Gurung, M, Baker, S, Neuzil, K, Shretha, S, Basnyat, B, Pollard, AJ

“…Similar rates of adverse events were noted in the two trial groups; fever developed in 5.0% of participants in the TCV group and 5.4% in the MenA vaccine group in the first week after vaccination. …”

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. by Jeppesen, C, Snape, M, Robinson, H, Gossger, N, John, T, Voysey, M, Ladhani, S, Okike, I, Oeser, C, Kent, A, Oliver, J, Taylor, P, Morales-Aza, B, Clarke, S, Casey, M, Martins, F, Kitchin, N, Anderson, A, Jones, H, Jansen, K, Eiden, J, Pedneault, L, Heath, P, Finn, A, Faust, S, Pollard, A

“…Studies assessing vaccine impact should use molecular methods to detect carriage.…”

Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal by Shakya, M, Colin-Jones, R, Theiss-Nyland, K, Voysey, M, Pant, D, Smith, N, Liu, X, Tonks, S, Mazur, O, Farooq, YG, Clarke, J, Hill, J, Adhikari, A, Dongol, S, Karkey, A, Bajracharya, B, Kelly, S, Gurung, M, Baker, S, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ, Tyvac Nepal Study Team

“…Similar rates of adverse events were noted in the two trial groups; fever developed in 5.0% of participants in the TCV group and 5.4% in the MenA vaccine group in the first week after vaccination. …”

Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a by Darton, T, Jones, C, Blohmke, C, Waddington, C, Zhou, L, Peters, A, Haworth, K, Sie, R, Green, C, Jeppesen, C, Moore, M, Thompson, B, John, T, Kingsley, R, Yu, L, Voysey, M, Hindle, Z, Lockhart, S, Sztein, M, Dougan, G, Angus, B, Levine, M, Pollard, A

“…Twenty-eight days after vaccination, participants were challenged with 104CFU S. …”

Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias by Voysey, M, Sadarangani, M, Pollard, A, Fanshawe, T

“…In the development of new vaccines, understanding the level of vaccine-induced antibody that is sufficient to protect against disease can simplify and expedite the development and licensing process. …”

Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV) by Voysey, M, Pollard, A

“…<strong>Background</strong> Salmonella Typhi is the major cause of enteric fever in lower income countries. New conjugate vaccines show promise as public health interventions, however there are no efficacy data available from endemic areas. …”

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults by Costa Clemens, SA, Marchevsky, N, Kelly, S, Felle, S, Eldawi, A, Rajasingam, R, Mahmud, R, Lambe, T, Voysey, M, Gonzalez, I, Milan, EP, Justino, MC, Bibi, S, Aley, P, Clemens, R, Pollard, AJ

“…<p>In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, S&atilde;o Paulo, Brazil) at least 4 months previously. …”

Association of antibody-dependent neutrophil phagocytosis with distinct antibody glycosylation profiles following typhoid vaccination by Johnson, M, Stockdale, LK, de Haan, N, Wuhrer, M, Nouta, J, Koeleman, CAM, Clarke, J, Marinou, S, Shakya, M, Colin-Jones, R, Theiss-Nyland, K, Voysey, M, Jin, C, Pant, D, Jones, E, Kelly, S, Dongol, S, Karkey, A, Shrestha, S, Basnyat, B, Hill, J, Pollard, AJ

“…Typhoid Vi-conjugate vaccines (Vi-TCV) have been developed to control typhoid fever in children in endemic regions. …”